How should a hordeolum (stye) be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Hordeolum (Stye)

Start with warm compresses applied for 5-10 minutes several times daily combined with eyelid hygiene using mild soap or commercial eyelid cleansers, followed by gentle massage to express the obstructed gland. 1

Initial Conservative Management

The cornerstone of hordeolum treatment is conservative therapy, which resolves most cases within approximately one week:

  • Apply warm compresses to the affected eyelid for 5-10 minutes, multiple times per day to increase blood circulation and relieve pain 1, 2
  • Clean eyelid margins with mild soap or commercial eyelid cleansers after warm compress application 1, 2
  • Perform gentle massage of the affected area following warm compresses to help express the obstructed gland 1, 2
  • Discontinue eye makeup during active infection 1
  • Never squeeze or attempt to "pop" the hordeolum, as this spreads infection 1

Escalation to Pharmacologic Therapy

If conservative measures are insufficient after 48 hours, consider advancing treatment 1:

Topical Antibiotics

  • Use topical antibiotics for moderate to severe cases or when signs of spreading infection are present 1, 2
  • Azithromycin ophthalmic solution has demonstrated efficacy with complete resolution in treated cases of internal hordeolum 3

Systemic Antibiotics

  • Reserve oral antibiotics for severe cases with spreading infection or systemic symptoms 1
  • Immunocompromised patients (diabetes, HIV, chemotherapy) require systemic antibiotics in addition to topical therapy due to risk of aggressive infection 1

Management of Underlying Conditions

Aggressively treat underlying blepharitis and meibomian gland dysfunction to prevent recurrence, as bacterial blepharitis is the most common predisposing factor 3, 1:

  • Implement a more aggressive eyelid hygiene regimen for recurrent hordeola 1, 2
  • Evaluate for meibomian gland dysfunction, which frequently contributes to repeated stye formation 1
  • Screen for ocular rosacea, particularly in patients with recurrent disease 1
  • Consider addressing moderate to severe blepharitis prior to intraocular surgical procedures to reduce endophthalmitis risk 3

Critical Red Flags Requiring Referral

Refer to ophthalmology immediately for any of the following warning signs 3, 1, 2:

  • Marked asymmetry or resistance to therapy 3, 2
  • Unifocal recurrent lesions, especially in the same location in elderly patients (raises suspicion for sebaceous carcinoma) 3, 2
  • Eyelid margin distortion, lash loss (madarosis), or ulceration 3, 2
  • Unilateral chronic blepharitis unresponsive to therapy 3, 2

Special Population Considerations

Immunocompromised Patients

  • Require systemic antibiotics in addition to topical therapy 1
  • Avoid aggressive eyelid manipulation to reduce risk of serious secondary infections 1
  • Monitor closely for progression to cellulitis 1

Pediatric Patients

  • Children with history of styes have increased risk of developing adult rosacea 4, 1
  • Evaluate for chronic blepharokeratoconjunctivitis, which may present with recurrent conjunctivitis and keratitis 2

Common Pitfalls to Avoid

  • Failing to distinguish hordeolum from chalazion: Hordeolum has rapid onset with acute inflammation and pain, while chalazion has gradual onset and is painless 1, 2
  • Missing underlying chronic blepharitis that predisposes to recurrent disease 1, 2
  • Overlooking sebaceous carcinoma in recurrent unilateral disease resistant to therapy, particularly in elderly patients 1, 2
  • Prolonged conservative management beyond 4-6 weeks without reassessment delays diagnosis of potential malignancy 2

Evidence Quality Note

While the American Academy of Ophthalmology guidelines provide clear treatment recommendations 3, 1, 2, Cochrane systematic reviews found no randomized controlled trials supporting or refuting the effectiveness of non-surgical interventions for acute internal hordeolum 5, 6. Despite the lack of high-quality trial evidence, the guideline recommendations reflect expert consensus and standard clinical practice that has proven effective in real-world settings.

References

Guideline

Treatment of Hordeolum

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Chalazion and Hordeolum Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Symptoms and Features of Hordeolum

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Interventions for acute internal hordeolum.

The Cochrane database of systematic reviews, 2013

Research

Non-surgical interventions for acute internal hordeolum.

The Cochrane database of systematic reviews, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.